^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADU-1805

    i
    Other names: ADU-1805, ADU 1805, ADU1805
    Associations

    News

    Trials
    Company:
    Exelixis, Sairopa
    Drug class:
    SIRPA antagonist
    Related drugs:
    Associations

    News

    Trials
    1m
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Sairopa B.V. | N=90 --> 130 | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ADU-1805
    over2years
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, Sairopa B.V. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • ADU-1805
    over2years
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Sairopa B.V.
    New P1 trial • Metastases
    |
    Keytruda (pembrolizumab) • ADU-1805